Preview

Вопросы современной педиатрии

Расширенный поиск

ФАКТОРЫ РИСКА РАННЕГО РАЗВИТИЯ КАРДИОВАСКУЛЯРНОЙПАТОЛОГИИ У ДЕТЕЙ, СТРАДАЮЩИХ ЮВЕНИЛЬНЫМ РЕВМАТОИДНЫМ АРТРИТОМ

Аннотация

Обзор посвящен проблеме изучения факторов риска раннего развития кардиоваскулярной патологии при ювенильном ревматоидном артрите. Приведены данные исследований, посвященных состоянию липидного обмена, дисфункции эндотелия, патологии системы гемостаза при ревматоидном артрите и ювенильном ревматоидном артрите. Прослежена взаимосвязь патогенеза атеросклероза и ювенильного ревматоидного артрита.
Ключевые слова: ювенильный ревматоидный артрит, атеротромбоз, атеросклероз.
(Вопросы современной педиатрии.-2007;6(5):74-80)

Об авторах

Е.Ю. Гудкова
Научный центр здоровья детей РАМН, Москва
Россия


Е.И. Алексеева
Научный центр здоровья детей РАМН, Москва
Россия


Список литературы

1. Клинические рекомендации. Ревматология. Под ред. Е.Л. Насонова М.: ГЭОТАР-Медиа. 2005.

2. Алексеева Е.И., Жолобова Е.С., Чистякова Е.Г, Бзарова Т.М. Ювенильный ревматоидный артрит. Учебно-методическое пособие. М. 2004.

3. Goodson N. Coronary artery disease and rheumatoid arthritis. Curr. Opin. Rheumatol. 2002; 14: 115–120.

4. Goodson N., Marks J., Lunt M. et al. Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Arthritis Rheum. 2005.

5. Pincus T., Sokka T., Wolfe F. Premature mortality in patients with rheumatoid arthritis: evolving concepts. Arthritis Rheum. 2001; 44: 1234-1236.

6. Maradit–Kremers H., Crowson C.S., Nicola P.J. et al. Increased unrecognized coronary heart disease and sudden death in rheumatoid arthritis. A population based controlled study. Arthritis Rheum. 2005; 52: 722–732.

7. Goodson N.J., Wiles N.J., Lunt M. et al. Mortality in Early inflammatory polyarthritis. Cardiovascular mortality is increased in seropositive patients. Arthritis Rheum. 2002; 46: 2010–2019.

8. Kitas G.D., Blank M.J., Bacon P.A. Cardiac involvement in rheumatoid disease. Clin. Med. JRCPL. 2001; 1: 18–21.

9. Van Dorum S., McColl G., Wicks I.P. Accelerated atherosclerosis. An exraarticular feature of rheumatoid arthritis. Arthritis Rheum. 2002; 46: 862–875.

10. Kitas G.D., Erb N. Tackling ischemic heart disease in rheumatoid arthritis. Rheumatology. 2003; 42: 607–613.

11. Sattar N., McCrey D.W., Capell H., McInnes I.B. Explaining how “high-grade” systemic inflammation accelerated vascular risk in rheumatoid arthritis. Circulation. 2003; 108: 2957–2963.

12. Manzi S., Wasco M.C. Inflammation mediated rheumatic disease and atherosclerosis. Ann. Rheum. Dis. 2000; 59: 321–325.

13. Насонов Е.Л. Проблема атеротромбоза в ревматологии. Вестник РАМН. 2003; 7: 6-10.

14. Chung C.P., Avalos I., Raggi P. Atherosclerosis and inflammation: insights from rheumatoid arthritis. Clin. Rheumatol. 2007; 26 (8): 1228–1233.

15. Насонов Е.Л. Иммунологические маркеры атеросклероза. Терапевтический архив. 2002; 5: 80–85.

16. Szmitko P.E., Wang C.H., Weisel R.D. et al. New markers of inflammation and endothelial cell activation. Part I. Circulation. 2003; 108: 1917–1923.

17. Szmitko P.E., Wang C.H., Weisel R.D. et al. New markers of inflammation and endothelial cell activation, part II. Circulation. 2003; 108: 2041–2048.

18. Насонов Е.Л. Иммунологические маркеры атеросклероза. В кн.: Антифосфолипидный синдром. М.: Литера. 2004. С. 278–298.

19. Malle E., De Beer F.C. Human serum amyloid A protein: a promising acute-phase reactant for clinical practice. Eur. J. Clin. Invest. 1996; 26: 427–435.

20. Morrow D. L., Rifai N., Antman E.M. et al. Serum amyloid A predictive early mortality in acute coronary syndrome: a TIMI 11A sub study. Am. Coll. Cardiol. 2000; 35: 358–362.

21. Biasucci L., Liuzzo G., Grillo R. et al. Elevated levels of C-reactive protein at discharge in patient with unstable angina predict recurrent instability. Circulation. 1999; 99: 855–860.

22. Насонова В.А., Бунчук Н.В. Ревматические болезни. Руководство по внутренним болезням. М.: Медицина. 1997.

23. De Bendetti F., Massa M., Robbioni P. et al Correlation of serum interleukin-6 levels with joint involvement and trombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 1991; 34: 1158–1163.

24. Rooney M., David J., Symmons J. et al. Inflammatory cytokine responses in juvenile chronic arthritis. Br. J. Rheumatol. 1995; 34: 454–460.

25. De Bendetti F., Massa M., Pignatti P. et al. Serum soluble interleukin-6 receptor and interleukin-6 receptor complex in systemic juvenile rheumatoid arthritis. J. Clin. Invest. 1994; 93: 2114–2119.

26. Peake N.J., Khawaja K., Myeis A. Interleukin–6 signalling in juvenile rheumatoid arthritis is limited by proteolytically cleaved soluble interleukin–6 receptor. Rheumatology. 2006; 45 (12): 1485–1489.

27. Keul R., Heinrich P.C., Muller-Newen G. et al. A possible role of soluble interleukin–6 receptor in the pathogenesis of systemic onset juvenile chronic arthritis. Cytokine. 1998; 10: 729.

28. Ridker P.M., Rifai N., Stampfer M.J., Hennekens C.H. Plasma concentration of interleukin-6 and the risk of feature myocardial infarction among apparently healthy men. Circulation. 2000; 101: 1767–1772.

29. Harris T.B., Ferrucci I., Traxy R.P. et al. Associations of elevated interleukin-6 and C-protein levels with mortality in the elderly. Am. J. Med. 1999; 106: 506–512.

30. Lee W.Y., Allison M.A., Kim D.J. Association of interleukin–6 and C–reactive protein with subclinical carotid atherosclerosis (the Rancho Bernardo Study). Am. J. Cardiol. 2007; 99 (1): 99-102.

31. Rooney M., Varsani H., Martin K. et al. Tumour necrosis factor alpha and its soluble receptorsin juvenile chronic arthritis. Rheumatology (Oxford). 2000; 39: 432–438.

32. Gattorno M., Picco P., Buoncompagni A. et al. Serum p55 and p75 tumour necrosis factor receptors as markers of disease activity in juvenile chronic arthritis. Ann. Rheum. Dis. 1996; 55: 243.

33. Abramson S.B., Amin A. Blocking the effects of ИЛ 1 in rheumatoil arthritis protects bone and cartilage. Rheumatology (Oxford). 2002; 41 (9): 972–980.

34. Cassidy P., Lindsley L. Textbook of Pediatric Rheumatology. 5th edition. USA. 2006.

35. Kavanaugh A. Anakinra (interleukin-1 receptor antagonist) has positive effects on function and quality of life in patient with rheumatoid arthritis. Adv. Ther. 2006; 23 (2): 208–217.

36. Weiss G., Willei J., Kiechl S. et al. Increased concentrations of neopterin in carotid atherosclerosis. Atherosclerosis. 1994; 106: 263–271.

37. Erren M., Reinecke H., Junker R. et al. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral artheries. Artherioscler. Thromb. Vasc. Biol. 1999; 19: 338–339.

38. Garica-Moll N., Coccolo F., Cole D et al. Serum neopterin and complexes stenosis morphology in patients with unstable angina. Artherioscler. Thromb. Vasc. Biol. 2000; 35: 956–962.

39. Gurfinkel E.P., Scirica B.M., Borovich G. et al Serum neopterin levels and the angiographic extent of coronary arterial narrowing in instable angina pectoris and non-Q wave acute myocardial infarction. Am. J. Cardiol. 1999; 83: 515–518.

40. Насонов Е.Л., Самсонов М.Ю., Tilz G., Fuhs D. Неоптерин — новый иммунологический маркер аутоиммунных ревматических заболеваний. Клиническая медицина. 2000; 8: 43–46.

41. Moncada S., Palmer R.M.J., Higgs E.A. Biosynthesis of nitric oxide from L–arginine: a pathway for the regulation of cell function and communication. Biochem. Pharmacol. 1989; 38: 1709–1715.

42. Palmer R.M.J., Mineau F., Ranger P et al. L-arginine is the physiological precursor for the formation of nitric oxide in endothelium dependent relaxation. Biochem. Biophys. Res. Comm. 1988; 153: 1251–1256.

43. Горрен А.К.Ф., Майер Б. Универсальная и комплексная энзимология синтазы азота // Обзор. Биохимия. 1998; 7: 870–880.

44. Das P., Schurman D.J., Lane S.R. Nitric oxide and G proteins mediate the response of bovine articular chondrocytes to fluid-induced shear. J. Orthop. Res. 1997; 15: 87–93.

45. Lotz M., Bober L., Narula S. et al ИЛ 17 promotes cartilage degradation (abstract). Arth. Rheum. 1996; 39: 120.

46. Rediske J., Koehne C., Zhang B. et al. Inducible production of nitric oxide by articular cell types. Osteoarthrit. Cart. 1994; 2: 199–206.

47. Charles I.S., Palmer R.M., Hickery M.S. et al. Cloning, characterization and expression of cDNA encoding an inducible nitric oxide synthase from the human chondrocyte. Proc. Nat. Acad. Sci. 1993; 90: 11419–11423.

48. Maier R., Bilbe G., Rediske J. et al. Inducible nitric oxide syntase from human articular chondrocytes: cDNA cloning and analysis of mRNA expression. Biochem. Biophys. Acta. 1994; 1208: 145–150.

49. Mendes A.F., Carvalho A.P., Caramona M.M. et al. Role of nitric oxide in activation of NF-kappa B, AP-1 and NOS II expression in articular chondrocytes. Inflamm. Res. 2002; 51 (7): 369–375.

50. McCartney-Francis N., Allen J.B., Mizel D.E. et al. Suppression of arthritis by an inhibitor of nitric oxide synthase. J. Exp. Med. 1993; 178: 149–154.

51. Stefanovic-Racic M., Meyers K., Meschter C. et al. N–monomethyl arginine, an inhibitor of nitric oxide synthase, suppresses the development of adjuvant arthritis in rats. Arthritis Rheum. 1994; 37: 1062–1069.

52. Ialenti A., Moncada S., Di Rosa M. et al. Modulation of adjuvant arthritis by endogenous nitric oxide. Br. J. Pharmacol. 1993; 110: 701–706.

53. van`t Hof R.J., Hocking L., Wright P.K. et al. Nitric oxide is a mediator of apoptosis in the rheumatoid joint. Rheumatology. 2000; 39: 1004–1008.

54. Veihelmann A., Hofbauer A., Krombach F. et al. Differencial function of nifric oxide in murine antigen-induced arthritis. Rheumatology. 2002; 41: 509–517.

55. Ling S., Lai A., Borschukova O. et al. Activation of nitric oxide signaling by the rheumatoid arthritis shared epitope. Arthritis. Rheum. 2006; 54 (11): 3423–3432.

56. Holoshitz J., Ling S. et al. Nitric oxide signaling triggered by the rheumatoid arthritis shared epitope: a new paradigm for MHC disease association? Ann. N.Y. Acad. Sci. 2007; 1110: 73–83.

57. Bica B.E., Gomes N.M., Fernandes P.D. et al. Nitric oxide levels and the severity of juvenile idiopathic arthritis. Rheumatol. Int. 2007; 27 (9): 819–825.

58. Braumvald E. Shattuck lecture cardiovascular medicine at the turn of millennium: triumph, concerns, and opportunities. N. Engl. J. Med. 1997; 337: 1360–1369.

59. Насонов Е. Л. Атеротромбоз при ревматических заболеваниях: анализ патогенеза. Терапевтический архив. 1998; 9: 95–98.

60. Shwager I., Jungi T.W. Effect of human recombinant cytokines of the induction of macrophage procoagulant activity. Blood. 1994; 83: 152–160.


Для цитирования:


Гудкова Е., Алексеева Е. ФАКТОРЫ РИСКА РАННЕГО РАЗВИТИЯ КАРДИОВАСКУЛЯРНОЙПАТОЛОГИИ У ДЕТЕЙ, СТРАДАЮЩИХ ЮВЕНИЛЬНЫМ РЕВМАТОИДНЫМ АРТРИТОМ. Вопросы современной педиатрии. 2007;6(5):74-80.

For citation:


Gudkova E., Alexeeva E. RISK FACTORS OF EARLY CARDIOVASCULAR PATHOLOGY OF CHILDREN SUFFERING FROM JUVENILE RHEUMATIC ARTHRITIS. Current Pediatrics. 2007;6(5):74-80.

Просмотров: 149


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1682-5527 (Print)
ISSN 1682-5535 (Online)